For this purpose, we extended our study to examine the anti-cancer effect of G28UCM on HER2+ breast cancer cells (AU565) that were continuously exposed in culture medium supplemented with trastuzumab (AU565TR) or lapatinib (AU565LR) over a period of at least six months. The gene discussed is ERBB2; the disease is breast cancer.